The efficacy of molnupiravir in patients with COVID-19

interventional Randomization: Randomized, Blinding: Double bli 2-3 Inclusion criteria: Living in a family with at least one infected person with COVID-19 Not having pulmonary involvement Not having symptoms like chest wall pain and dysnea suggesting pulmonary involvement Positive PCR test of COVID-19 Patient with COVID-19 symptoms lesser than 3 days Patients satisfied with consumption of oral medication Blood oxygen saturation above 93 percents Exclusion criteria: Patients under 18 years old Having underlying diseases such as uncontrolled diabetes, uncontrolled blood pressure, liver and heart disease and kidney, heart and liver failure History of any of the diseases including hepatitis B or C, HIV, autoimmune diseases and immunodeficiency History of hepatocellular disease, liver failure and heart failure of liver tests more than 3 times normal History of allergy to antiviral drugs Existence of thrombocytopenia (platelets under 100000) History of recent COVID-19 vaccination lesser than 7 days being pregnant breastfeeding COVID-19. COVID-19, virus identified;U07.1 Intervention 1: Intervention group: The group receiving oral molnopiravir 200 mg daily for up to five days after the intervention, with diphenhydramine syrup / vitamin C tablet / vitamin D tablet / famotidine 40 mg tablet every 12 hours (in case of fever and pain Muscle naproxen 250 mg daily or twice daily will be added). Intervention 2: Control group: This group will receive placebo exactly similar to molnopiravir for five days, with diphenhydramine syrup, vitamin C tablets, vitamin D tablets, famotidine 40mg tablets every 12 hours, and naproxen 250 in case of fever and muscle aches. They will receive it once or twice a day. Negative pcr test or increase in CT NUMBER after intervention. Timepoint: Before and after the intervention. Method of measurement: According to the throat sample of patients with Covid-19, which is taken from patients in the same conditions in the specialized virology laboratory of Baqiyatallah Medical Center.;Fever. Timepoint: Upon arrival and after five days. Method of measurement: with a standard thermometer.;Serum CRP inflammatory factor. Timepoint: Upon arrival and after five days. Method of measurement: By a valid laboratory.;The level of oxygen saturation in the blood of patients. Timepoint: Upon arrival and after five days. Method of measurement: By standard pulse oximeter.;Dry cough existance. Timepoint: Upon arrival and after five days. Method of measurement: patient report and researcher observe.;Dyspnea. Timepoint: Upon arrival and after five days. Method of measurement: patient report and researcher observe.;Muscular pain. Timepoint: Upon arrival and after five days. Method of measurement: patient report and researcher observe.;Pulse rate. Timepoint: Upon arrival and after five days. Method of measurement: researcher measure.;Respiratory rate. Timepoint: Upon arrival and after five days. Method of measurement: researcher measure.;Blood pressure. Timepoint: Upon arrival and after five days. Method of measurement: researcher measure.;Serum ESR inflammatory factor. Timepoint: Upon arrival and after five days. Method of measurement: By a valid laboratory.